Kornimate/medical-research-clean huggingface dataset:
medications with or without weightwatchers

Conditions: Obesity; Overweight

Summary: the study compares the effectiveness of adults living with overweight or obesity taking weight management medications alone vs taking them with behavioral and lifestyle support. the primary outcome is percent body weight lost at 12-weeks.


Eligibility criteria:
inclusion criteria: * bmi of \>30 or bmi of \>27 with one or more weight related medically qualifying condition (hypertension, dyslipidemia, sleep apnea, cardiovascular disease) * determined eligible for bupropion/naltrexone or liraglutide by ww clinic medical provider and initiated a medication management plan exclusion criteria: * diabetes * uncontrolled hypertension * history of seizures * history of glaucoma * history of chronic kidney disease * currently taking bupropion * currently taking naltrexone * current or previous history of anorexia or bulimia nervosa * engagement with vomiting or laxative use within the last 28 days with the aim of controlling their shape or weight * currently taking opioids * previous surgical obesity treatment * use of other anti-obesity medication in last 90 days or a glp1 in the last 180 days * lost weight \>11 lbs in the last 90 days * pregnant, breastfeeding, intends to become pregnant, of child-bearing potential and not using a highly effective contraceptive method * any other reason rendering a participant unsuitable for trial participation, as determined by a clinician or study investigator
a study to access the safety and tolerability of rn316 (pf-04950615) when administered to healthy adult subjects

Conditions: Healthy

Summary: the study is designed to determine the safety and tolerability of rn316 when administered intravenously to healthy adult subjects. this is the first time rn316 has been given to humans.


Eligibility criteria:
inclusion criteria: * healthy, ambulatory men and women (of non-childbearing potential) ages 18 -70 inclusive. * baseline total cholesterol ≥ 200 mg/dl, baseline ldl ≥ 130 mg/dl. * bmi 18.5 to 35, and body weight ≤150 kg, inclusive. exclusion criteria: * evidence of clinically significant disease that may increase the risk to the subject of study participation or interfere with interpretation of results. * secondary hyperlipidemia. * subjects who have taken lipid lowering compounds within the past 12 months prior to dosing.

Keywords: endocrinology; hypercholesterolemia; hyperlipidemia; lipid metabolism disorders rn316 pf-04950615
prospective trial on eosinophilia in non-small cell lung cancer (nsclc).

Conditions: Non-small Cell Lung Cancer

Summary: this prospective study will examine eosinophils in various biological materials to compare the detection in those materials and ascertain the prognostic and predictive role of eosinophils in untreated non-small cell lung cancer patient.


Eligibility criteria:
inclusion criteria: * o all stages of nsclc * stage iii-iv nsclc eligible for ici treatment * 18 years or older; non pregnant women * in stage iii-iv: no previous ici and before ici (mono- or combination therapy) initiation * signed informed consent * clinical, biological and radiological evaluation at the chu de liège for at least 6 months following treatment initiation exclusion criteria: * probable noncompliance with the follow-up requirements of the study (psychiatric condition, socio-economic factors) * inclusion in a clinical study contraindicating the enrolment in the proteon study
efficacy of inhaling bronchodilator medications in chronic obstructive pulmonary disease

Conditions: Chronic Obstructive Pulmonary Disease

Summary: some patients with chronic obstructive pulmonary disease (copd) report that they are uncertain whether they achieve clinical benefit using a dry-powder inhaler (dpi). one possible explanation is that the patient is unable to inhale the dry powder bronchodilator medication into the lower respiratory tract due to a low peak inspiratory flow rate (pifr). a pifr \< 60 l/min is considered to be suboptimal flow for a dpi, including the diskus device. the hypothesis of the study is that the forced expiratory volume in 1 second (fev1) measured at two hours after inhalation of the study medication will be higher with arformoterol solution (15 mcg) from a nebulizer compared with salmeterol dry powder (50 mcg) inhaled from the diskus.


Eligibility criteria:
inclusion criteria: * male or female patient 60 years of age or older; diagnosis of copd; current or former smoker; previous or current use of diskus device; pifr \< 60 l/min using the in-check dial against the resistance of the diskus device; clinically stable. exclusion criteria: * any patient who has a concomitant disease that might interfere with study procedures or evaluation; inability to withhold short-acting and long-acting bronchodilators on the days of testing

Keywords: breathing difficulty
flow arrest safety and technical success with balloon guide catheters

Conditions: Acute Ischemic Stroke

Summary: the objective of this post-market registry is to assess technical efficacy and safety associated with the use of the boss balloon guide catheter during neuro-vascular procedures while providing temporary arrest of blood flow.

this is a prospective, multi-center, non-randomized observational registry evaluating use of boss balloon guide catheters in patients diagnosed with an acute ischemic stroke due to large intracranial vessel occlusion.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke vessel occlusion (ica, m1 or m2) of the anterior circulation with associated symptoms * adult patient willing to provide informed consent * pre-treatment national institutes of health stroke scale (nihss) ≥ 6 exclusion criteria: * posterior circulation stroke * tandem occlusions * cervical carotid stenosis * participating in another clinical trial
comparison of two interdental cleaners

Conditions: Gingivitis

Summary: comparison of two interdental cleaning devices on plaque removal, gingivitis and bleeding.

this study measured plaque accumulation, bleeding on probing and gingivitis using the rustogi modification of the navy plaque index, bop and modified gingival index at baseline, 2-weeks and 4-weeks.

Eligibility criteria:
inclusion criteria: * healthy adult * non smoker * available for 4-weeks * able to provide written informed consent. * minimum of 20 natural teeth. * minimum requirement for plaque, gingivitis and bleeding. exclusion criteria: * medical condition * no antibiotics within 6 months of study start * not on any medication (impact oral health).
coronary ct angiography for improved assessment of suspected acute coronary syndrome

Conditions: Acute Coronary Syndrome; Chest Pain

Summary: current evaluation of patients suspected of non-st-elevation acute coronary syndrome is greatly dictated by the results of high-sensitivity troponins. in a substantial number of patients this approach does not provide a conclusive work-up. patients typically present with slightly elevated high-sensitivity troponins without significant changes during serial sampling and no other clinical clues that can aid in determining the etiology of their chest pain complaints. uncertainty remains about the optimal diagnostic management of these patients and they are often admitted to undergo invasive angiography. coronary ct angiography can improve efficiency of clinical care in these patients by reducing unnecessary hospital admissions and invasive angiography. in this study, the investigators will investigate whether a diagnostic strategy comprising of early coronary ct angiography is more clinically efficient than standard optimal care in patients with an inconclusive work-up for non-st-elevation acute coronary syndrome.


Eligibility criteria:
inclusion criteria: * patients presenting to the emergency department with symptoms suggestive of nste-acs. they do not fulfil criteria for either "rule-in" or "rule-out" nste-acs based on serial sampling of high-sensitivity troponins and standard clinical work-up. exclusion criteria: * inability or unwillingness to provide informed consent. * history of proven cad, defined as documented prior myocardial infarction, percutaneous coronary intervention or coronary artery bypass graft surgery. * previous examination with either invasive angiography or ccta in the last 3 years. * clinical instability: clinical heart failure, hemodynamic instability, severe chest pain. * ccta-specific contra-indications: * allergy to iodine contrast media * pregnancy * impaired renal function: estimated glomerular filtering rate \<60% of the age-corrected normal values * severe arrhythmia likely to affect image interpretation * bmi \> 40 * inability to cooperate during the examination.

Keywords: coronary ct angiography high-sensitivity troponin diagnosis
lymphocyte markers as predictors of responsiveness to rituximab among patients with idiopathic nephrotic syndrome

Conditions: Nephrotic Syndrome

Summary: the purpose of this study is to investigate if lymphocyte markers predict response to rituximab among patients with idiopathic nephrotic syndrome


Eligibility criteria:
inclusion criteria: * age 1-18 years old at the time of diagnosis of nephrotic syndrome * steroid-dependent (sdns) or steroid-resistant nephrotic syndrome (sdns) exclusion criteria: * egfr \<60 ml/min per 1.73m2 * infantile onset of nephrotic syndrome * nephrotic syndrome secondary to chronic infections such as hepatitis b, hepatitis c or human immunodeficiency virus, systemic lupus erythematosus, henoch-schönlein purpura, iga nephropathy, membranoproliferative glomerulonephritis or membranous nephropathy * current or previous therapy for tuberculosis * presence of mutations in wt1, nphs1, nphs2 and trpc6.
consequences of conjugal bereavement in adults

Conditions: Bereavement; Depressive Disorder; Immunologic Disease; Mental Disorder; Sleep Disorder

Summary: bereavement refers to the expected reactions and sadness associated with the loss of a loved one. it has been reported that the loss of a spouse is rated as the major life stressor among survivors of varying ages and diverse cultural backgrounds. statistics have shown that in the united states over 800,000 men and women lose a spouse each year. a wide range of symptoms has been associated with bereavement including; depressed mood, tearfulness, sleep disturbances, and irrational behavior. previous studies have shown that up to 50% of bereaved individuals can develop major depression. bereavement has also been associated with dysfunction of the immune system. as a result, bereaved adults are more vulnerable to infection. however, the exact relationship between bereavement and immunity is uncertain. researchers firmly believe that a relationship does exist between stress, more specifically bereavement, immunity, and the increased chance of dying following the loss of a long-term spouse. the objective of this study is to find possible links between bereavement, depression, and the immune system. this study will follow a group of elderly bereaved spouses and a group of elderly people who have not lost a long-term spouse. the group of bereaved individuals will be followed for approximately 13 months after the loss of their spouse and the group of controls will be followed for 13 months after entering the study. researchers will make note of any clinical, biological, and immunological changes in any participants of the study.

it is estimated that over 800,000 men and women become bereaved each year in the united states (larue et al, 1985). while the near certainty of such bereavement is predictable in one spouse or the other, the exact impact and duration of bereavement is much less predictable (stroebe et al, 1995). it has been reported that the loss of a spouse is rated as the major life stressor among survivors of varying ages and diverse cultural backgrounds (holmes and rahe, 1967). as one copes with the loss of a loved one, expected reactions include sadness, tearfulness, and even depression (deleon, 1994; pasternak, 1996). other complications can include work-related difficulties, sleep disturbances, irrational behaviors, and immunologic dysfunction (zisook, 1994; prigerson, et al, 1995). all of these symptoms are common; yet, the underlying biology and relationship with the time course of bereavement are still poorly understood. the purpose of this study will be to prospectively follow a cohort of elderly bereaved spouses and controls from multiple clinical and biological perspectives over thirteen months after the loss of a spouse.

Eligibility criteria:
people over the age of 50 who have lost their spouse within the last three months.

Keywords: bereavement depression suicide activity of daily living immune function occupational performance sleep disorders mood changes
evaluation of a fasting mimicking diet

Conditions: Coronary Artery Disease

Summary: randomized, open-label, 7-month trial in eighty (80) adult subjects. forty (40) subjects will be randomized to the intervention fmd arm with a 5 day meal program every month for four (4) months. forty subjects will be randomized to a follow a mediterranean diet plan for four months. both arms will have a final study visit at month 7.

determine the effects of the fmd on cardiovascular (cv) biomarkers, coronary heart disease (chd) risk factors (body weight, body mass index (bmi), body composition, blood pressure, serum lipid levels and dysglycemia blood measurements), noninvasive cardiovascular testing for endothelial function, arterial stiffness of large and small arteries and autonomic function testing in adult subjects over a seven-month study period.

Eligibility criteria:
inclusion criteria: * body mass index equal to or greater than 28 * endopat® score for endothelial function of less than or equal to 2.0 or ac 2 small resistance artery compliance by computerized arterial pulse wave analysis (capwa) of less than or equal to 5.0. * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * individuals who are allergic to tree nuts (macadamia, cashew, almond, pecan), soy, oats, sesame, or celery/celeriac * pregnant females * any cancer within the past 5 years * documented myocardial infarction within past 5 years * documented cerebrovascular accident within past 5 years * chronic steroid use (longer than 45 consecutive days * type i insulin-dependent diabetes mellitus
evaluation of long-term digital childhood obesity treatment

Conditions: Childhood Obesity; Treatment Adherence

Summary: this study aims to evaluate if a web-based digital support system aiming to replacing or complement standardized pediatric behavioural obesity treatment. the hypothesis is that a digital system of communication between the family and the clinic can generate improved treatment results (change in bmi sds) and reduce the number of missed visits.

childhood obesity treatment is time consuming for both the health care system, and for the involved families. there is an association between the intensity and the outcome of treatment. in this study all children who start treatment for childhood obesity will use a digital support system as a complement to behavioral treatment. the digital support system includes daily weighing on scales that do not show any digits, linked to a mobile app where weight development is shown as a moving average in the form of bmi standard deviation score (sds). the app also provides an individual target curve visualizing the expected weight journey. weight in growing children is complex to interpret why bmi sds is used. objective data from scale are automatically transferred to the database and the clinic and the family have direct contact with the clinic via the app. the present study is a continuation of the investigators previous one-year study, clinicaltrials.gov id: nct04323215. in this follow-up study, the investigators aim to assess the treatment outcomes over a three-year period. the evaluation will be carried out on 107 children who underwent digi-physical treatment for three years. the results will be compared with a matched control group (n=321) from the swedish childhood obesity treatment register, boris.

Eligibility criteria:
inclusion criteria: * obesity according to international obesity task force (iotf) exclusion criteria: * none

Keywords: mobile health support system behavioral treatment self-monitoring
comparison of costoclavicular brachial plexus block and supraclavicular brachial plexus block

Conditions: Phrenic Nerve Paralysis

Summary: the investigator will compare costoclavicular approach of infraclavicular block and supraclavicular block. especially, the incidence of phrenic nerve palsy and the quality of block.

costoclavicular brachial plexus block is a recently developed approach of infraclavicular brachial plexus block. using ultrasound, all of 3 cords are well visible in single plane. compared to conventional infraclavicular block, it needs smaller amount of local anesthetics. supraclavicular brachial plexus block is known as spinal anesthesia of upper extremities. it provides fast and good quality of anesthesia and analgesia. but some studies showed that there are over 50% of phrenic nerve palsy in supraclavicular block. in this study, the investigator will compare phrenic nerve palsy incidence and block quality between costoclavicular block and supraclavicular block using ultrasound.

Eligibility criteria:
inclusion criteria: * asa i or ii * scheduled for surgery of hand or forearm exclusion criteria: * patient refusal * neuromuscular disease * pregnancy * previous history of surgery of periclavicular region * nerve injury history * bleeding tendency * allergy to local anesthetics * other contraindication of regional anesthesia

Keywords: costoclavicular block
effects of niacin on intramyocellular fatty acid trafficking in upper body obesity and type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus; Obesity

Summary: muscle insulin resistance is a hallmark of upper body obesity (ubo) and type 2 diabetes (t2dm). it is unknown whether muscle free fatty acid (ffa) availability or intramyocellular fatty acid trafficking is responsible for the abnormal response to insulin. likewise, the investigators do not understand to what extent the incorporation of ffa into ceramides or diacylglycerols (dg) affect insulin signaling and muscle glucose uptake. the investigators will measure muscle ffa storage into intramyocellular triglyceride, intramyocellular fatty acid trafficking, activation of the insulin signaling pathway and glucose disposal rates under both saline control (high overnight ffa) and after an overnight infusion of intravenous niacin (lower/normal ffa) to provide the first integrated examination of the interaction between ffa and muscle insulin action from the whole body to the cellular/molecular level. by identifying which steps in the insulin signaling pathway are most affected, the investigators will determine the site-specific effect of ceramides and/or dg on different degrees of insulin resistance. hypothesis 1: greater trafficking of plasma ffa into intramyocellular dg will impair proximal insulin signaling and reduce muscle glucose uptake. hypothesis 2: lowering ffa in ubo and t2dm by using an intravenous infusion of niacin will alter trafficking of plasma ffa into intramyocellular ceramides in a way that will improve insulin signaling and increase muscle glucose uptake. hypothesis 3: lowering ffa in ubo and t2dm by using an intravenous infusion of niacin will alter trafficking of plasma ffa into intramyocellular dg in a way that will improve insulin signaling and increase muscle glucose uptake.


Eligibility criteria:
inclusion criteria: * women and men (women premenopausal) * bmi 29-37 * weight stable * not pregnant/nursing exclusion criteria: * ischemic heart disease * atherosclerotic valvular disease * smokers (\>20 cigarettes per week) * bilateral oophorectomy * concomitant use of medications that can alter serum lipid profile: * high dose fish oil (\>3g per day), * statins (if yes hold for 6 weeks and receive pcp's approval), * niacin * fibrates * thiazolidinediones * beta-blockers * atypical antipsychotics * lidocaine or niacin/niaspan allergy * subjects with 1.5 times upper limit of normal of serum creatinine, alkaline phosphatase, aspartate aminotransferase (ast), alanine aminotransferase (alt) unless participant has fatty liver disease, total bilirubin (unless the patient has documented gilbert's syndrome)
pilot study based on technology solutions for hypertension care

Conditions: Hypertension; Blood Pressure

Summary: the goal of this clinical trial is to understand whether the adoption of digital solutions by healthcare professionals and patients improves the management of patients with high blood pressure. the main questions it aims to answer are: * are these digital solutions feasible and well accepted by patients? * can these solutions, compared to standard care, allow a better hypertension control in patients with high blood pressure? participants randomised to one of the two intervention arms will be asked to adopt the digital solutions that include a smartphone app and 2 devices for blood pressure and body weight measurement that will be connected to the app. researchers will compare patients randomised in the two intervention groups with patients randomised to standard care (control group)

the study falls within the scope of the hsmonitor project, a pre-commercial tender for the development of telematics solutions aimed at optimising patient health status and disease management. specifically, the aim of this study is to test whether the adoption of hsmonitor solutions by healthcare professionals and patients improves the management of patients with high blood pressure. this will be a randomised controlled trial where patients with hypertension will be randomised either to one of the two digital solutions or to standard care. the present pilot study is planned to be carried out within the framework of the eu project hsmonitor - pre-commercial procurement of innovative ict-enabled monitoring to improve health status and optimize hypertension care (grant agreement nr. 856698). the two solutions are referred to as: * solution 1 - hsmartbpm (developed by a supplier consortium led by gnomon) * solution 2 - hyperhealth (developed by a supplier consortium led by tech4care)

Eligibility criteria:
inclusion criteria: * diagnosed with essential hypertension (\>140/90 mmhg or normal bp with antihypertensive treatment) * basic ict knowledge and ability to access the internet at home and on mobile devices * aged 18+ * ability to provide written informed consent, giving informed consent. * written informed consent exclusion criteria: * inability to consent * chronic renal replacement therapy (haemodialysis, peritoneal dialysis or transplantation) or if, at baseline, there is a history of active malignancy within the last five years * pregnancy * illiterate * younger than 18 years * being a prisoner * being institutionalized * the patient is mentally or psychiatrically ill * the patient has barriers to understand the implications of participation to the study * the patient is critically ill or dying * the patient is extremely poor * the patient has a learning disability * the patient is sedated or unconscious * the patient is a refugee with no permanent permission to stay * the patient does not have a good command of the language * the patient has problems in cognitive, juridical, and deferential dimensions

Keywords: digital technology hypertension blood pressure